Molecular Imaging in Cardiology — MCQs
Best way to localize extra-adrenal pheochromocytoma:
The most sensitive and practical technique for detection of myocardial ischemia in the perioperative period is -
For pericardial calcifications, which is the best investigation?
Which imaging modality delivers the highest dose of radiation?
A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?
In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?
A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?
A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?
A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?
A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?
Molecular Imaging in Cardiology Indian Medical PG Practice Questions and MCQs
Question 1: Best way to localize extra-adrenal pheochromocytoma:
- A. X-ray
- B. Clinical examination
- C. VMA excretion
- D. Nuclear medicine scan (MIBG scan) (Correct Answer)
Explanation: ***Nuclear medicine scan (MIBG scan)*** - **Iodine-131-metaiodobenzylguanidine (MIBG) scan** is the imaging modality of choice for localizing extra-adrenal pheochromocytomas due to its high specificity for **neuroendocrine tumors** like pheochromocytomas and paragangliomas. - MIBG is structurally similar to **norepinephrine** and is actively taken up by adrenergic neurons, allowing visualization of hypersecreting chromaffin cells wherever they are located in the body. *X-ray* - **X-rays** provide limited soft tissue detail and are generally not useful for localizing pheochromocytomas, especially extra-adrenal ones. - They may show calcifications in some tumors but lack the sensitivity and specificity needed for definitive localization. *Clinical examination* - A **clinical examination** can identify signs and symptoms suggestive of pheochromocytoma (e.g., hypertension, palpitations, sweating) but cannot localize the tumor itself. - Localization requires **imaging studies** due to the variable and often deep-seated location of these tumors. *VMA excretion* - **Vanillylmandelic acid (VMA) excretion** is a biochemical test used to diagnose pheochromocytoma by measuring catecholamine metabolites in urine. - While it confirms the presence of a catecholamine-secreting tumor, it provides **no information about the tumor's location**.
Question 2: The most sensitive and practical technique for detection of myocardial ischemia in the perioperative period is -
- A. Direct measurement of end diastolic pressure
- B. Radio labeled lactate determination
- C. Magnetic Resonance Spectroscopy
- D. Regional wall motion abnormality detected with the help of 2D transoesophageal echocardiography (Correct Answer)
Explanation: ***Regional wall motion abnormality detected with the help of 2D transesophageal echocardiography*** - **Transesophageal echocardiography (TEE)** provides high-resolution images of the heart, allowing for the sensitive detection of **regional wall motion abnormalities (RWMA)**, an early and practical indicator of myocardial ischemia in the perioperative setting. - The development of new or worsening RWMA is often the **first sign of ischemia**, preceding ECG changes or hemodynamic alterations, making it a highly sensitive and clinically useful tool. *Direct measurement of end-diastolic pressure* - While an elevated **end-diastolic pressure** can indicate ventricular dysfunction, it is an **indirect sign** and not specific enough for early myocardial ischemia detection. - This measurement often requires invasive monitoring, which is less practical for routine detection compared to TEE. *Radio-labeled lactate determination* - **Lactate production** can increase in ischemic tissue, but its detection is a **biochemical marker** that typically lags behind the onset of ischemia. - This technique is generally **research-oriented** and not a practical, bedside method for rapid perioperative ischemia detection. *Magnetic Resonance Spectroscopy* - **Magnetic Resonance Spectroscopy (MRS)** can provide detailed metabolic information about tissue, including changes related to ischemia. - However, it is a **complex, time-consuming, and expensive imaging modality** that is not practical for routine, real-time perioperative monitoring of myocardial ischemia.
Question 3: For pericardial calcifications, which is the best investigation?
- A. Ultrasound
- B. CT scan (Correct Answer)
- C. MRI
- D. Transesophageal echocardiography
Explanation: ***Correct: CT scan*** - **CT scans** are highly sensitive and specific for detecting **pericardial calcifications** due to their excellent spatial resolution and ability to measure calcium density (Hounsfield units). - They provide detailed anatomical information about the **pericardium** and can accurately map the extent, location, and thickness of calcified areas. - **CT is the gold standard** for detecting and quantifying pericardial calcification, particularly in constrictive pericarditis. *Incorrect: Ultrasound* - While ultrasound (echocardiography) can visualize the pericardium and may detect calcifications, its ability to definitively identify and characterize **calcifications** is limited compared to CT. - **Acoustic shadowing** from calcifications can obscure underlying structures, making a precise assessment challenging. - Useful for detecting pericardial effusion and thickening, but not optimal for calcification assessment. *Incorrect: MRI* - **MRI excels** in visualizing soft tissues, pericardial inflammation, and fluid collections, but it is **poor at detecting calcium**. - Calcifications typically appear as signal voids (black) on MRI, making it difficult to differentiate them from other structures, air, or motion artifacts. - MRI is valuable for assessing pericardial inflammation and constriction but not the preferred method for calcification. *Incorrect: Transesophageal echocardiography* - TEE offers high-resolution images of cardiac structures and is primarily used for assessing valve function, intracardiac masses, endocarditis, and aortic pathology. - Its utility in detecting and characterizing **pericardial calcifications** is limited compared to CT, especially for diffuse or subtle calcifications. - The pericardium is not optimally visualized with TEE compared to transthoracic echocardiography.
Question 4: Which imaging modality delivers the highest dose of radiation?
- A. Cardiac perfusion scan (Correct Answer)
- B. CT scan of the chest
- C. Mammogram
- D. CT scan of the brain
Explanation: ***Cardiac perfusion scan*** - A **cardiac perfusion scan (nuclear cardiology)** involves the administration of a radioactive tracer, and the radiation dose can be significant due to the nature and energy of the isotopes used. - While varying, the effective dose for these scans can range from **10 to 30 mSv**, placing it among some of the highest radiation exposures from medical imaging. *CT scan of the chest* - A **CT scan of the chest** provides a relatively high radiation dose compared to plain X-rays, typically ranging from **5 to 7 mSv**. - This is generally lower than some nuclear medicine studies, particularly complex or prolonged cardiac perfusion scans. *Mammogram* - A **mammogram** involves a relatively low dose of radiation, typically in the range of **0.2 to 0.7 mSv**. - Its objective is to image the breast tissue with minimal exposure, making it one of the lower-dose imaging modalities available. *CT scan of the brain* - A **CT scan of the brain** usually delivers a moderate radiation dose, estimated to be around **1 to 2 mSv**. - This is often less than a chest CT due to the smaller volume and different shielding considerations, and significantly less than a cardiac perfusion scan.
Question 5: A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?
- A. 64Cu for longer imaging window despite inferior image quality
- B. 64Cu because shorter positron range improves resolution
- C. 18F for better spatial resolution despite requiring on-site cyclotron (Correct Answer)
- D. 18F because longer half-life allows delayed imaging
Explanation: ***18F for better spatial resolution despite requiring on-site cyclotron*** - **18F** has a shorter **positron range** compared to **64Cu**, which minimizes the distance the positron travels before annihilation, leading to superior **spatial resolution**. - While it necessitates proximity to a **cyclotron** due to a 110-minute half-life, this timeframe is sufficient for most **hypoxia imaging** tracers to reach a high **target-to-background ratio**. *64Cu for longer imaging window despite inferior image quality* - **64Cu** provides a longer imaging window due to its **12.7-hour half-life**, but its longer **positron range** leads to increased **blurring** and poorer resolution. - For diagnostic **tumor hypoxia**, the extra-long window is often unnecessary and leads to a higher **absorbed radiation dose** for the patient. *64Cu because shorter positron range improves resolution* - This statement is factually incorrect as **64Cu** actually has a significantly longer **effective positron range** than **18F**. - Higher **energy positrons** travel further in tissue, which degrades the **image quality** by misplacing the site of annihilation relative to the source. *18F because longer half-life allows delayed imaging* - This is incorrect as **18F** has a much shorter half-life (**110 minutes**) compared to the **12.7 hours** of **64Cu**. - The shorter half-life of **18F** prevents very late delayed imaging but helps in keeping the total **patient radiation exposure** lower.
Question 6: In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?
- A. 18F-PSMA with 4 hour delayed imaging
- B. 68Ga-PSMA with 3 hour uptake time without furosemide
- C. 68Ga-PSMA with 1 hour uptake time and furosemide administration (Correct Answer)
- D. 18F-PSMA with 30 minutes uptake time and forced hydration
Explanation: ***68Ga-PSMA with 1 hour uptake time and furosemide administration*** - An **uptake time of 60 minutes** is the standard for **68Ga-PSMA**, providing an optimal **target-to-background ratio** (TBR) while maintaining efficient clinical workflow. - The administration of **furosemide** (a loop diuretic) promotes **urinary washout** of the tracer, reducing interfering **bladder activity** and lowering the radiation dose to the urinary tract. *18F-PSMA with 4 hour delayed imaging* - While **18F-labeled tracers** have a longer half-life, a 4-hour delay is excessive and leads to significant **decay of activity**, potentially requiring higher initial doses and increasing **radiation exposure**. - Such long delays are not practical for routine clinical protocols and do not provide a significant clinical advantage over standard 1-2 hour imaging for most **PSMA** ligands. *68Ga-PSMA with 3 hour uptake time without furosemide* - **68Ga** has a short physical half-life (68 minutes), so a 3-hour wait significantly reduces the **count rate**, leading to poor **image quality** due to increased noise. - Omitting **furosemide** results in high tracer concentration in the **bladder**, which can obscure local recurrence in the **prostate bed** or nearby pelvic lymph nodes via **halo artifacts**. *18F-PSMA with 30 minutes uptake time and forced hydration* - A **30-minute uptake time** is generally insufficient for optimal **tracer internalization** into prostate cancer cells, resulting in a lower **tumor-to-background ratio**. - Although **forced hydration** helps, it is less effective than **furosemide** at rapidly clearing the high-intensity tracer from the **distal ureters** and bladder during the peak imaging window.
Question 7: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?
- A. Progressive disease requiring treatment escalation
- B. Treatment-induced necrosis with favorable prognosis (Correct Answer)
- C. Flare phenomenon indicating treatment response
- D. Infection complicating the metastasis
Explanation: ***Treatment-induced necrosis with favorable prognosis*** - A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase. - The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure. *Progressive disease requiring treatment escalation* - Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor. - Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**. *Flare phenomenon indicating treatment response* - The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients). - In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare. *Infection complicating the metastasis* - An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells. - There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.
Question 8: A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?
- A. High grade aggressive tumor
- B. Well-differentiated slow-growing tumor (Correct Answer)
- C. Necrotic tumor with inflammation
- D. False positive DOTATATE scan
Explanation: ***Well-differentiated slow-growing tumor*** - High **DOTATATE uptake** indicates dense expression of **somatostatin receptors (SSTRs)**, which is a hallmark of well-differentiated neuroendocrine tumors. - Low **FDG uptake** (low SUVmax) reflects a low rate of glucose metabolism, signifying a **low-grade (G1/G2)** tumor with a slow proliferation rate. *High grade aggressive tumor* - Aggressive, high-grade neuroendocrine carcinomas (G3) typically show high **FDG avidity** because they rely heavily on glycolysis for energy. - These tumors often lose their **somatostatin receptor expression**, leading to low or absent uptake on a **DOTATATE scan**. *Necrotic tumor with inflammation* - **Necrosis** generally presents as a photopenic (cold) area in the center of a lesion on PET imaging, not intense DOTATATE uptake. - **Inflammation** would typically result in increased **FDG uptake** due to high metabolic activity in activated leukocytes, rather than isolated high DOTATATE avidity. *False positive DOTATATE scan* - Intense uptake with an **SUVmax of 45** is highly specific for SSTR-rich tissues and is considered diagnostic for neuroendocrine pathology in this clinical context. - A **gastrinoma** is a known neuroendocrine tumor (NET) that consistently expresses these receptors, making a false positive highly unlikely.
Question 9: A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?
- A. Administer insulin and delay scan until glucose <150 mg/dL (Correct Answer)
- B. Double the FDG dose to compensate
- C. Cancel scan and reschedule after glucose control
- D. Proceed immediately with scanning
Explanation: ***Administer insulin and delay scan until glucose <150 mg/dL*** - **Hyperglycemia** causes competitive inhibition of **FDG uptake** in tumor cells, as glucose and FDG compete for the same **GLUT transporters**. - Administering insulin lowers blood glucose to an acceptable range (ideally **<150 mg/dL**) to ensure optimal **diagnostic accuracy** and image quality, though scanning should occur at least 2 hours after insulin administration to avoid muscle uptake. *Double the FDG dose to compensate* - Increasing the **FDG dose** does not bypass the competitive inhibition caused by serum glucose and will only increase **radiation exposure** unnecessarily. - High blood sugar levels will still prioritize **native glucose** over FDG into cells, resulting in a poor **signal-to-noise ratio**. *Cancel scan and reschedule after glucose control* - While long-term control is ideal, acute management with **short-acting insulin** allows the scan to proceed on the same day once levels fall below the threshold. - Rescheduling is only necessary if the patient's **blood glucose** remains persistently high and unresponsive to immediate clinical intervention. *Proceed immediately with scanning* - Scanning with a glucose level of **220 mg/dL** leads to poor image quality and potential **false-negative** results due to diminished tracer uptake in the lymphoma. - Elevated **endogenous glucose** saturates the receptors, preventing the radioactive tracer from adequately labeling the **metabolically active** tumor sites.
Question 10: A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?
- A. Both primary and nodal metastasis (Correct Answer)
- B. Primary tumor with false positive node
- C. Dual primary malignancies
- D. Primary tumor only, node is inflammatory
Explanation: ***Both primary and nodal metastasis*** - In lung cancer staging, a **Standardized Uptake Value (SUVmax)** greater than 2.5 in mediastinal lymph nodes is highly suspicious for **metastatic involvement**. - The node's SUVmax of 4.2 relative to the primary tumor's high uptake (8.5) strongly indicates **metabolically active disease** at both the primary and nodal sites. *Primary tumor with false positive node* - **False positives** on PET often occur due to granulomatous disease or infection, but an SUVmax of 4.2 in a known cancer context is more likely **metastatic**. - Without history of **sarcoidosis** or active infection, the metabolic activity in the lymphatic basin of the primary tumor is considered malignant until proven otherwise. *Dual primary malignancies* - Two separate primary malignancies would typically involve different anatomical sites or different **histological features**, rather than a primary and its draining node. - The presence of a mediastinal node in a patient with a known lung mass is the classic presentation of **regional spread** (N staging), not a second primary site. *Primary tumor only, node is inflammatory* - While inflammation can cause **FDG avidity**, an SUVmax of 4.2 is significantly high and less typical for purely reactive or **incidental inflammatory** nodes. - Relying on an inflammatory interpretation without biopsy would risk **understaging** the patient's lung cancer, as the node meets the metabolic criteria for malignancy.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free